Evotec, Second Genome to collaborate on finding treatments for microbiome-mediated diseases

By Zachary Brennan

- Last updated on GMT

Evotec, Second Genome to collaborate on finding treatments for microbiome-mediated diseases

Related tags Evotec Partnership

Evotec and Second Genome have agreed to partner in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. 

The collaboration will work to identify novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's approach to identify and modulate microbiome-mediated pathways will be enhanced by Evotec's integrated drug discovery platform. The agreement triggers an undisclosed upfront payment for Evotec, which is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.

The microbiome field is new to Evotec, but Second Genome is an expert on this field​,” Evotec spokesman Gabriele Hansen told Outsourcing-Pharma.com.

As part of the partnership, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said in a statement: "We are pleased to contribute to Second Genome's unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut​."

This latest deal for Evotec is just one of a flurry of recent partnerships that the company has formed. Earlier this year, Padlock Therapeutics extended its relationship with Evotec​ after prior success, and the European CRO also saw successes from its partnerships with Bayer and Janssen​. Evotec also entered into negotiations in December for a major strategic relationship with Sanofi​ that could be worth more than $300m.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Related suppliers

Follow us


View more